ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- NPC2 deficiency as a potential target drives malignancy and chemo-resistance in DLBCL.Biology direct · 2026Article
- Recent advances in the construction of humanized animal models and applications in translational medicine.Animal models and experimental medicine · 2026Review
- The role of immune cells in Hantaan-induced hemorrhagic fever with renal syndrome.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Human common cold coronaviruses (CCCoVs, e.g., 229E, NL63, OC43, HKU1) hold critical yet underexplored significance in understanding coronavirus evolutionary dynamics and immune cross-protection, offering insights for predicting emerging pathogens and developing pan-coronavirus vaccines. However, research is hindered by the lack of animal models due to strict human-specific tropism and the confounding effects of frequent co-infections from clinical samples, which obscure virus-specific pathogenesis. Although lung-humanized mice have been used in SARS-CoV-2 studies, their application to CCCoVs remains unvalidated and relies on logistically challenging fresh human tissues. This study optimizes a transplantation strategy using cryopreserved human fetal lung tissue, achieving enhanced engraftment efficiency. And the refined model supports robust infection by all four major CCCoVs and demonstrates the therapeutic efficacy of Paxlovid against HKU1. Furthermore, comparative analysis reveals phenotypic distinctions in human immune cells between native mouse lungs and human lung implants in lung-immune dual-humanized mice. The model also enables validation of virus-specific T cell responses and assessment of SARS-CoV-2 cross-reactivity post-HKU1 infection. Overall, this study establishes a scalable platform using cryopreserved tissues for respiratory virus research, overcoming prior limitations in modeling human-specific tropism and dissecting immune-pathogen interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.